Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both

Objective: To examine the neuropsychological profile of dementia patients from a community-based autopsy sample of dementia, comparing Alzheimer disease (AD), Lewy body pathology (LBP) alone, and LBP with coexistent AD (AD/LBP). Methods: The authors reviewed 135 subjects from a community-based study of dementia for whom autopsy and brain tissue was available. Diagnostic groups were determined according to standard neuropathologic methods and criteria, and the presence of LBs was determined using α-synuclein immunostaining. Neuropathologically defined diagnostic groups of AD, AD/LBP, and LBP were examined for differences on neuropsychological test performance at the time of initial study enrollment. Results: There were 48 patients with AD alone, 65 with LB and AD pathology (AD/LBP), and 22 with LBP alone (LBP alone). There were no significant differences between groups demographically or on performance of enrollment Mini-Mental State Examination (MMSE) or Dementia Rating Scale (DRS). AD patients performed worse than the LBP patients on memory measures (Fuld Object Memory Evaluation Delayed Recall, Wechsler Memory Scale Logical Memory Immediate and Delayed Recall; p < 0.05) and a naming task (Consortium to Establish a Registry for Alzheimer’s Disease Naming; p < 0.05). LBP patients were more impaired than AD patients on executive function (Trail Making Test Part B; p < 0.05) and attention tasks (Wechsler Adult Intelligence Scale–Revised Digit Span; p < 0.05). Decline in MMSE and DRS scores over time were greatest in the patients with AD/LBP. Conclusions: In a community-based sample of older, medically complicated patients with dementia, there are neuropsychological differences between dementia subtypes at the time of diagnosis. In particular, patients with Alzheimer disease (AD) alone and AD/Lewy body pathology (LBP) had more severe memory impairment than patients with LBP. LBP alone was associated with more severe executive dysfunction. Patients with AD/LBP had the most rapid rate of cognitive decline.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  J. Trojanowski,et al.  Antibodies to α‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease , 1999, Annals of neurology.

[3]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[4]  A. Berardelli,et al.  Central effects of botulinum toxin type A: Evidence and supposition , 2004, Movement disorders : official journal of the Movement Disorder Society.

[5]  L. Thal,et al.  The Lewy body variant of Alzheimer's disease , 1990, Neurology.

[6]  I. McKeith,et al.  Systematic Review and Meta-Analysis Show that Dementia with Lewy Bodies Is a Visual-Perceptual and Attentional-Executive Dementia , 2003, Dementia and Geriatric Cognitive Disorders.

[7]  K. Marder,et al.  Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia , 2004, Movement disorders : official journal of the Movement Disorder Society.

[8]  A. Larner MMSE subscores and the diagnosis of dementia with Lewy bodies , 2003, International journal of geriatric psychiatry.

[9]  R. R. Abidin Psychological Assessment Resources , 1995 .

[10]  R Bucks,et al.  Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. , 2001, Archives of neurology.

[11]  Murat Emre,et al.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study , 2000, The Lancet.

[12]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[13]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[14]  L. Thal,et al.  Cognitive decline is faster in Lewy body variant than in Alzheimer's disease , 1998, Neurology.

[15]  N. Butters,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery , 1994, Neurology.

[16]  Douglas Galasko,et al.  Neuropsychological Deficits Associated with Diffuse Lewy Body Disease , 1996, Brain and Cognition.

[17]  R. Reitan Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[18]  C. Pieper,et al.  Comparison of Lewy body variant of Alzheimer’s disease with pure Alzheimer’s disease , 1999, Neurology.

[19]  Florence Pasquier,et al.  Early diagnosis of dementia: neuropsychology , 1999, Journal of Neurology.

[20]  K. Jellinger Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies , 2004, Neurology.

[21]  D W Dickson,et al.  DLB fluctuations , 2004, Neurology.

[22]  R. Hamilton,et al.  Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.

[23]  Toshiki Nakai,et al.  Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies , 2002, Journal of the Neurological Sciences.

[24]  J Q Trojanowski,et al.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. , 1998, The American journal of pathology.

[25]  Eric Mormont,et al.  Profils mnésiques différents dans la démence à corps de Lewy et la maladie d'Alzheimer débutantes. , 2003 .

[26]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[27]  G. Belle,et al.  University of Washington Alzheimer’s Disease Patient Registry (ADPR): 1987–8 , 1990, Aging.

[28]  M. Yamada,et al.  [Dementia rating scale]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.